Table 1.
Clinical Neurologic Features and Comorbidities of Patients with COVID-19
| Features | n (%) |
|---|---|
| Clinical manifestations | |
| Altered mental status | 26 (96.3) |
| Dysgeusia | 1 (3.7) |
| Generalized weakness | 1 (3.7) |
| Headache | 2 (7.4) |
| Focal deficit | 10 (37.0) |
| Decerebrate posturing | 1 (3.7) |
| Facial droop | 1 (3.7) |
| Fixed pupils | 1 (3.7) |
| Gaze deviation | 3 (11.1) |
| Hemineglect | 2 (7.4) |
| Hemiparesis or hemiplegia | 4 (14.9) |
| Quadriplegia | 1 (3.7) |
| Comorbidities | |
| Acute ischemic stroke | 3 (11.1) |
| Acute myocardial infarction | 1 (3.7) |
| Atrial fibrillation | 2 (7.4) |
| Chronic kidney disease | 6 (22.2) |
| Chronic myeloid leukemia | 1 (3.7) |
| Congestive heart failure | 2 (7.4) |
| Coronary artery disease | 2 (7.4) |
| Diabetes mellitus type 2 | 14 (51.9) |
| Fungal meningitis | 1 (3.7) |
| Hypertension | 17 (63.0) |
| Intravenous drug abuse | 1 (3.7) |
| Neuromyelitis optica | 1 (3.7) |
| Obesity | 7 (25.9) |
| Orthotopic heart transplant | 1 (3.7) |
| Pseudotumor cerebri | 1 (3.7) |
| Systemic lupus erythematous | 1 (3.7) |
N denotes total number of patients with documentation of said finding, and % is relative to all critical patients with COVID-19 with clear neurologic involvement.
COVID-19, coronavirus disease 2019.